ADMA Biologics (NASDAQ:ADMA) Shares Gap Down - Time to Sell?

Key Points

• Shares plunged after a short‑seller report: ADMA gapped down (opened near $8.98) following a Culper Research report, and although the company disputed the allegations the rebuttal hasn't stopped the selloff; multiple law firms have opened investigations and short interest is elevated (~11.3% of float), raising legal and volatility risk.
• Mixed market signals with speculative interest: Zacks upgraded ADMA to a "Strong Buy" calling it deeply oversold, and unusual options activity (≈22,398 calls, +848% vs. average) shows speculative bullish positioning that could amplify swings but is risky.
• Fundamentals and analyst view: ADMA reported in‑line EPS and 18.4% revenue growth, has a $1.9B market cap and a consensus target of $32, but the stock trades well below its 50/200‑day moving averages and analyst opinions remain mixed (two Strong Buy, two Hold).

ADMA Biologics Inc (NASDAQ:ADMA - Get Free Report)'s stock price gapped down prior to trading on Thursday . The stock had previously closed at $9.63, but opened at $8.98. ADMA Biologics shares last traded at $8.0240, with a volume of 12,613,001 shares trading hands.

Key Headlines Impacting ADMA Biologics

Here are the key news stories impacting ADMA Biologics this week:

• Positive Sentiment: Zacks added ADMA to its Rank #1 (Strong Buy) list on March 25, which can attract bargain‑hunters and momentum buyers. New Strong Buy Stocks for March 25th
• Positive Sentiment: Zacks also published a piece noting ADMA is deeply oversold and "ripe for a turnaround," highlighting technical oversold conditions and upward analyst estimate revisions that could support a rebound. Down 27% in 4 Weeks, Here's Why ADMA Looks Ripe for a Turnaround
• Positive Sentiment: Unusual options activity: investors bought ~22,398 call contracts on March 26 (≈+848% vs. average call volume), signaling speculative bullish interest or hedging ahead of potential news — this can amplify intraday volatility and short‑squeeze dynamics.
• Neutral Sentiment: Cantor Fitzgerald reaffirmed a "neutral" rating on ADMA, which is unlikely to drive a directional move but frames investor expectations. Benzinga
• Negative Sentiment: A short‑seller report by Culper Research (Mar 24) triggered a sharp selloff and headlines about alleged issues; media coverage notes shares plunged on those allegations. This is the primary catalyst for today's weakness. Shares plunge on short‑seller allegations
• Negative Sentiment: ADMA publicly disputed the short‑seller report, calling parts misleading and saying the Board is reviewing assertions — but the rebuttal has not fully reversed the market reaction. ADMA Addresses Misleading Short‑Seller Report
• Negative Sentiment: Multiple law firms (Pomerantz, Frank R. Cruz, Ademi LLP) have launched shareholder investigations and securities‑fraud inquiries into ADMA, increasing legal and disclosure risk and pressuring the stock. Pomerantz investigation Frank R. Cruz investigation Ademi LLP investigation
• Negative Sentiment: Short interest surged in March (reports show ~25.8M shares short as of Mar 13, ~11.3% of float), indicating heavy bearish positioning that can both pressure the stock and fuel volatility if shorts cover.

Analyst Upgrades and Downgrades

Several brokerages have recently commented on ADMA. Zacks Research upgraded ADMA Biologics from a "hold" rating to a "strong-buy" rating in a research note on Monday, March 2nd. Wall Street Zen raised shares of ADMA Biologics from a "hold" rating to a "buy" rating in a research report on Saturday, February 28th. Weiss Ratings reaffirmed a "hold (c)" rating on shares of ADMA Biologics in a report on Tuesday, December 23rd. Finally, Cantor Fitzgerald reiterated a "neutral" rating on shares of ADMA Biologics in a research note on Thursday. Two analysts have rated the stock with a Strong Buy rating and two have issued a Hold rating to the stock. Based on data from MarketBeat.com, the company has a consensus rating of "Buy" and a consensus target price of $32.00.

ADMA Biologics Stock Performance

The company has a market cap of $1.90 billion, a P/E ratio of 13.29 and a beta of 0.51. The stock's 50-day moving average price is $15.95 and its 200-day moving average price is $16.52. The company has a debt-to-equity ratio of 0.16, a current ratio of 6.71 and a quick ratio of 3.74.

ADMA Biologics (NASDAQ:ADMA - Get Free Report) last issued its quarterly earnings data on Wednesday, February 25th. The biotechnology company reported $0.20 earnings per share for the quarter, hitting the consensus estimate of $0.20. ADMA Biologics had a net margin of 28.80% and a return on equity of 37.52%. The business had revenue of $139.16 million during the quarter, compared to analysts' expectations of $139.80 million. During the same quarter in the previous year, the company earned $0.46 EPS. The business's revenue was up 18.4% on a year-over-year basis. Equities analysts anticipate that ADMA Biologics Inc will post 0.51 EPS for the current year.

Insider Buying and Selling at ADMA Biologics

In other ADMA Biologics news, COO Kaitlin M. Kestenberg-Messina sold 10,096 shares of the firm's stock in a transaction dated Monday, March 9th. The shares were sold at an average price of $15.63, for a total value of $157,800.48. Following the transaction, the chief operating officer directly owned 466,600 shares of the company's stock, valued at $7,292,958. This trade represents a 2.12% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Steve Elms bought 7,000 shares of the company's stock in a transaction dated Thursday, March 5th. The stock was purchased at an average price of $15.67 per share, with a total value of $109,690.00. Following the completion of the transaction, the director directly owned 2,038,730 shares in the company, valued at approximately $31,946,899.10. This represents a 0.34% increase in their position. Additional details regarding this purchase are available in the official SEC disclosure. 3.50% of the stock is owned by insiders.

Hedge Funds Weigh In On ADMA Biologics

Institutional investors have recently added to or reduced their stakes in the stock. Salomon & Ludwin LLC acquired a new position in ADMA Biologics in the 3rd quarter worth about $25,000. Rothschild Investment LLC boosted its stake in shares of ADMA Biologics by 373.8% during the third quarter. Rothschild Investment LLC now owns 1,895 shares of the biotechnology company's stock valued at $28,000 after purchasing an additional 1,495 shares in the last quarter. Summit Securities Group LLC bought a new stake in shares of ADMA Biologics during the fourth quarter worth about $29,000. Clearstead Advisors LLC raised its holdings in ADMA Biologics by 55.7% in the 3rd quarter. Clearstead Advisors LLC now owns 2,222 shares of the biotechnology company's stock valued at $33,000 after buying an additional 795 shares during the last quarter. Finally, iSAM Funds UK Ltd acquired a new stake in ADMA Biologics during the 3rd quarter worth approximately $34,000. 75.68% of the stock is currently owned by institutional investors and hedge funds.

ADMA Biologics Company Profile

ADMA Biologics, Inc is a biopharmaceutical company headquartered in Ramsey, New Jersey, that focuses on the development, manufacturing and commercialization of specialty plasma-derived biologics for the treatment of primary immunodeficiency and infectious diseases. Leveraging an integrated model that spans plasma collection, fractionation, formulation and fill-finish operations, ADMA Biologics aims to address unmet needs in immune-compromised and high-risk patient populations.

The company's marketed product portfolio includes BIVIGAM, a human immunoglobulin intravenous (IGIV) therapy approved by the U.S.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.